This web page was created programmatically, to learn the article in its authentic location you may go to the hyperlink bellow:
https://www.acc.org/Latest-in-Cardiology/Articles/2026/08/10/13/07/eagles-eye-view-12aug2026
and if you wish to take away this text from our web site please contact us
In this week’s View, Dr. Eagle appears to be like on the broad variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve substitute (TAVR). Next, he examines PARTNER-3, a 7-year research on TAVR versus surgical aortic valve substitute (SAVR) outcomes in low-risk sufferers. He then provides a perspective on the impact of intercourse distinction and delayed prognosis in sufferers with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the possible SAMCRO trial which evaluates way of life intervention along with medical remedy in sufferers with invasively confirmed angina with no obstructive coronary artery illness (ANOCA).
X Links:
Clinical Topics:
Anticoagulation Management, Cardiac Surgery, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Cardiac Surgery and Heart Failure, Acute Heart Failure, Diet
Keywords:
EaglesEyeView, National Cardiovascular Data Registries, STS/ACC TVT Registry, Platelet Aggregation Inhibitors, Transcatheter Aortic Valve Replacement, Patient Reported Outcome Measures, Diet, Mediterranean, Anticoagulants, Heart Disease Risk Factors, Fibrinolytic Agents, Health Status, Delayed Diagnosis, Heart Failure, Cardiomyopathies, Risk Factors, Interventional Cardiology, Registries
This web page was created programmatically, to learn the article in its authentic location you may go to the hyperlink bellow:
https://www.acc.org/Latest-in-Cardiology/Articles/2026/08/10/13/07/eagles-eye-view-12aug2026
and if you wish to take away this text from our web site please contact us
